galectin.jpg
Galectin Therapeutics to Present at 4th Global NASH Congress
April 27, 2021 09:28 ET | Galectin Therapeutics Inc.
NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...
galectin.jpg
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
March 04, 2021 08:00 ET | Galectin Therapeutics Inc.
NORCROSS, Ga., March 04, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes,...
galectin.jpg
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
December 11, 2020 08:00 ET | Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...
galectin.jpg
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020
November 09, 2020 08:00 ET | Galectin Therapeutics Inc.
Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated Board Member Joel Lewis Assumes CEO Role – Board Adds Two New Highly Accomplished Professionals NORCROSS, Ga., Nov. 09, 2020 ...
galectin.jpg
Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today
September 29, 2020 12:00 ET | Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that the Company will host...
galectin.jpg
Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
September 10, 2020 08:00 ET | Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
galectin.jpg
Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer
September 02, 2020 08:00 ET | Galectin Therapeutics Inc.
Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board Board strengthened in scientific expertise with addition of Dr. Elissa...
galectin.jpg
UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
June 30, 2020 09:05 ET | Galectin Therapeutics Inc.
Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this...
galectin.jpg
Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
June 30, 2020 08:00 ET | Galectin Therapeutics Inc.
Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this...
Logo.png
INmune Bio to Present at BIO CEO & Investor Conference
February 06, 2019 09:00 ET | INmune Bio, Inc.
LA JOLLA, CA, Feb. 06, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (Nasdaq: INMB) (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s...